X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aventis Pharma with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ACTAVIS (US) - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SANOFI INDIA   ACTAVIS
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
ACTAVIS
Dec-14
SANOFI INDIA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs4,56017,533-   
Low Rs4,40010,695-   
Sales per share (Unadj.) Rs1,028.53,157.2-  
Earnings per share (Unadj.) Rs129.0-394.0-  
Cash flow per share (Unadj.) Rs186.0289.7-  
Dividends per share (Unadj.) Rs68.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs753.66,847.8-  
Shares outstanding (eoy) m23.03265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.5 97.4%   
Avg P/E ratio x34.7-35.8 -97.0%  
P/CF ratio (eoy) x24.148.7 49.4%  
Price / Book Value ratio x5.92.1 288.4%  
Dividend payout %52.70-   
Avg Mkt Cap Rs m103,1743,752,831 2.7%   
No. of employees `0003.621.6 16.8%   
Total wages/salary Rs m3,5920-   
Avg. sales/employee Rs Th6,537.738,865.5 16.8%   
Avg. wages/employee Rs Th991.40-   
Avg. net profit/employee Rs Th819.8-4,850.0 -16.9%   
INCOME DATA
Net Sales Rs m23,686839,495 2.8%  
Other income Rs m708-2,095 -33.8%   
Total revenues Rs m24,394837,400 2.9%   
Gross profit Rs m5,281107,845 4.9%  
Depreciation Rs m1,313181,781 0.7%   
Interest Rs m1526,479 0.1%   
Profit before tax Rs m4,661-102,511 -4.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,520 0.0%   
Tax Rs m1,691-5,270 -32.1%   
Profit after tax Rs m2,970-104,760 -2.8%  
Gross profit margin %22.312.8 173.6%  
Effective tax rate %36.35.1 705.7%   
Net profit margin %12.5-12.5 -100.5%  
BALANCE SHEET DATA
Current assets Rs m15,673442,306 3.5%   
Current liabilities Rs m6,678322,571 2.1%   
Net working cap to sales %38.014.3 266.3%  
Current ratio x2.31.4 171.2%  
Inventory Days Days7658 131.0%  
Debtors Days Days2266 33.7%  
Net fixed assets Rs m8,098102,511 7.9%   
Share capital Rs m2300-   
"Free" reserves Rs m17,0880-   
Net worth Rs m17,3561,820,833 1.0%   
Long term debt Rs m0954,152 0.0%   
Total assets Rs m25,4003,336,988 0.8%  
Interest coverage x311.7-2.9 -10,856.6%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.90.3 370.7%   
Return on assets %11.8-2.3 -501.0%  
Return on equity %17.1-5.8 -297.4%  
Return on capital %26.9-3.0 -894.8%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Net fx Rs m2990-   
CASH FLOW
From Operations Rs m3,226144,158 2.2%  
From Investments Rs m-1,555-345,168 0.5%  
From Financial Activity Rs m-1,818193,935 -0.9%  
Net Cashflow Rs m-147-7,076 2.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare SANOFI INDIA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare SANOFI INDIA With: GSK PHARMA  FRESENIUS KABI ONCO.  ALKEM LABORATORIES  FDC LTD.  NATCO PHARMA  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 16, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - VENUS REMEDIES COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS